Evidence map›Paper›PMID 24813079›Full record

ReviewBlood cancer journal2014

Induced pluripotent stem cells in hematology: current and future applications.

D Focosi, G Amabile, A Di Ruscio, P Quaranta, D G Tenen, M Pistello

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood cancer journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Emergence of CD43-Expressing Hematopoietic Progenitors from Human Induced Pluripotent Stem Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017
    Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

D FocosiDivision of Transfusion Medicine and Transplant Biology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
G Amabile1] Harvard Medical School, Boston, MA, USA [2] Harvard Stem Cell Institute, Boston, MA, USA.
A Di Ruscio1] Harvard Medical School, Boston, MA, USA [2] Harvard Stem Cell Institute, Boston, MA, USA.
P QuarantaRetrovirus Centre and Virology Section, Department of Translational Research, University of Pisa, Pisa, Italy.
D G Tenen1] Harvard Medical School, Boston, MA, USA [2] Cancer Science Institute, National University of Singapore, Singapore, Singapore.
M PistelloRetrovirus Centre and Virology Section, Department of Translational Research, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reprogramming somatic cells into induced pluripotent stem (iPS) cells is nowadays approaching effectiveness and clinical grade. Potential uses of this technology include predictive toxicology, drug screening, pathogenetic studies and transplantation. Here, we review the basis of current iPS cell technology and potential applications in hematology, ranging from disease modeling of congenital and acquired hemopathies to hematopoietic stem and other blood cell transplantation.

Indexed as

AnimalsHematologyHematopoietic Stem Cell TransplantationHumansInduced Pluripotent Stem Cells

Identifiers

PMID24813079
PMCPMC4042300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.